ME01396B - Postupak za sintezu ivabradina i njegovih farmaceutski prihvatljivih aditivnih soli kiselina - Google Patents
Postupak za sintezu ivabradina i njegovih farmaceutski prihvatljivih aditivnih soli kiselinaInfo
- Publication number
- ME01396B ME01396B MEP-2007-219A MEP2007219A ME01396B ME 01396 B ME01396 B ME 01396B ME P2007219 A MEP2007219 A ME P2007219A ME 01396 B ME01396 B ME 01396B
- Authority
- ME
- Montenegro
- Prior art keywords
- formula
- compound
- reaction
- ivabradine
- vii
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 13
- 239000002253 acid Substances 0.000 title claims 4
- 150000003839 salts Chemical class 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 19
- HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 claims 8
- 238000006243 chemical reaction Methods 0.000 claims 7
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 claims 4
- CZLMRJZAHXYRIX-UHFFFAOYSA-N 1,3-dioxepane Chemical compound C1CCOCOC1 CZLMRJZAHXYRIX-UHFFFAOYSA-N 0.000 claims 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 238000005984 hydrogenation reaction Methods 0.000 claims 4
- 229960003825 ivabradine Drugs 0.000 claims 4
- 229960000504 ivabradine hydrochloride Drugs 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000033764 rhythmic process Effects 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- E—FIXED CONSTRUCTIONS
- E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
- E01C—CONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
- E01C11/00—Details of pavings
- E01C11/16—Reinforcements
- E01C11/165—Reinforcements particularly for bituminous or rubber- or plastic-bound pavings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Architecture (AREA)
- Civil Engineering (AREA)
- Structural Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Claims (18)
1. Postupak za sintezu ivabradina formule (I): ili 3{3-[{[(7S)-3,4dimetoksibiciklo[4.2.0]octa-1,35-trien-7-il]metil)(meti1)amino] propil)-7,8-dimetoksi-1,3,4,5-tetrahidro-2H-3-benzazepin-2-ona, njegovih farmaceutski prihvatljivih aditivnih soli kiselina i njihovih hidrata. naznačen time što podvrgava kompoziciju formule (V): u kojoj R 1 i R2, isti ili različiti, predstavljaju svaki jednu alkoksi (CrC8) grupu, linearnu ili razgranatu, ili pak obrazuju zajedno sa atomom ugljenika koji ih nosi jedan ciklični 1,3-đioxan, 1,3-dioksolan ili 1,3-dioksepan, jednoj reakciji katalitičke hiđrogenacije, a potom podvrgava ovako đobijenu kompoziciju formule (VI): u kojoj su R 1 i R2 kako su napred definisani, jednoj reakciji sa kompozicijom formule (VII) : u kojoj HX predstavlja jednu farmaceutski prihvatljivu kiselinu, u prisustvu vodonika i nekog katalizatora,za neposredno prevođenje, posle filtriranja i izolovanja katalizatora, u aditivnu so ivabratina sa kiselinom HX, koja se eventualno podvrgava, ukoliko se želi čist ivabradin, delovanju neke baze.
2. Postupak prema zahtevu l, naznačen time, što je katalizator za reakciju hidrogenizacije jedinjenja (V) paladijum na ugljeniku.
3. Postupak prema zahtevu l ili 2, naznačen time, što je tokom reakcije hidrogenizacije jedinjenja formule (V) pritisak vodonika od l do 220 bar.
4. Postupak prema bilo kom od zahteva l do 3, naznačen time, što je temperatura hidrogenizacije jedinjenja formule (V) od 20 do 100°C.
5. Postupak prema zahtevu 4, naznačen time, što je temperatura hidrogenizacije jedinjenja formule (V) od 40 do 80°C.
6. Postupak prema bilo kom od zahteva l do 5, naznačen time, što međujedinjenje formule (VI) nije izdvojeno.
7. Postupak prema bilo kom od zahteva l do 6, naznačen time, što je katalizator za reakciju između jedinjenja formule (VI) i jedinjenja formule (VII) paladijum na ugljeniku.
8. Postupak prema bilo kom od zahteva 1 do 7, naznačen time, što je tokom reakcije između jedinjenja formule (VI) i jedinjenja formule (VII) pritisak vodonika od 1 do 220 bar.
9. Postupak prema bilo kom od zahteva l do 7, naznačen time, što je temperatura reakcije između jedinjenja formule (VI) i jedinjenja formule (VII) od 30 do 120°C.
10. Postupak prema zahtevu 9, naznačen time, što je temperatura reakcije između jedinjenja formule (VI) i jedinjenja formule (VII) od 40 do 100°C.
11. Postupak prema bilo kom od zahteva l do 10, naznačen time, što koristi jedinjenja formula (Va) i (VIa), koja su posebni slučajevi jedinjenja formula (V) i (VI) kod kojih R 1 i R2 obrazuju zajedno sa atomom ugljenika koji ih nosi jedan ciklični 1,3-dioksan, 1,3-dioksolan ili 1,3-dioksepan.
12. Postupak prema bilo kom od zahteva 1 do ll, naznačen time, što koristi međujedinjenje formula (VIla), koje je poseban slučaj jedinjenja formule (VII) pri čemu HX predstavlja hlorovodoničnu kiselinu, tako da se dobija hlorhidrat ivabradina.
13. Jedinjenje formule (Va): (Va) kod koga R 1 i R2 obrazuju zajedno sa atomom ugljenika koji ih nosi jedan ciklični 1,3-dioksan, 1,3-dioksolan ili 1,3-dioksepan.
14. Jedinjenjie formule (VI): kod koga R 1 i R2, koji mogu biti isti ili različiti, i predstavljaju svaki jednu alkoksi (C1-C8) grupu, linearnu ili razgranatu, ili pak obrazuju zajedno sa atomom ugljenika koji ih nosi jedan ciklični 1,3-dioxan, 1,3-dioksolan ili 1,3-dioksepan,
15. Kristalni α: oblik hlorhidrata ivabradina formule (la): karakterističan je po sledećem dijagramu difrakcije X-zraka mereno na jednom difraktomeru PANalytical X'Pert Pro sa detektorom X'Celerator, izraženo preko položaja linija ( Bragg-ov ugao izražen u stepenima), visine linija (izraženo sabiranjem), površina linija(izražena kao zbirovi x stepeni), širina linija na polovini visine ("FWHM", izraženo u stepenima) i međuravansko odstojanje "d" (izraženo u A):
16. Farmaceutska kompozicija koja sadrži kao aktivni sastojak kristalni a oblik hlorhidrata ivabradina prema zahtevu 15, u kombinaciji sa jednim ili više farmaceutski prihvatljivih, inertnih i netoksičnih nosača.
17. Primena kristalnog a oblika hlorhidrata ivabradina prema zahtevu 15 u proizvodnji medikamenata koji se koriste kao sredstva za usporavanje rada srca.
18. Primena kristalnog u oblika hlorhidrata ivabradina prema zahtevu 15 u proizvodnji medikamenata koji se koriste za lečenje ili sprečavanje različitih kliničkih situacija isbemije miokarda kao što je angina pektoris, infarkt miokarda i sa njime povezani poremećaji ritma, kao i raznih patologija koje obuhvataju poremećaje ritma srca, naročito supraventrikularne poremećaje ritma, i kod srčane insuficijencije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0403830A FR2868777B1 (fr) | 2004-04-13 | 2004-04-13 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| EP05290381A EP1589005B1 (fr) | 2004-04-13 | 2005-02-21 | Procédé de synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01396B true ME01396B (me) | 2010-03-02 |
Family
ID=34941959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2007-219A ME01396B (me) | 2004-04-13 | 2005-02-21 | Postupak za sintezu ivabradina i njegovih farmaceutski prihvatljivih aditivnih soli kiselina |
Country Status (43)
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2868776B1 (fr) * | 2004-04-13 | 2008-04-18 | Servier Lab | Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2868775B1 (fr) * | 2004-04-13 | 2008-04-11 | Servier Lab | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2882554B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2882553B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2882556B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2882555B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2891826B1 (fr) | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| FR2891827B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2894826B1 (fr) * | 2005-12-21 | 2010-10-22 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent |
| ES2381771T3 (es) | 2006-11-30 | 2012-05-31 | Cadila Healthcare Limited | Procedimiento para la preparación de hidrocloruro de ivabradina |
| WO2008125006A1 (fr) * | 2007-04-12 | 2008-10-23 | Utopharm (Shanghai) Co., Ltd | Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable |
| US8212026B2 (en) | 2007-05-30 | 2012-07-03 | Ind-Swift Laboratories Limited | Process for the preparation of ivabradine hydrochloride and polymorph thereof |
| SI22750A (sl) * | 2008-04-07 | 2009-10-31 | Krka D.D. | Ivabradin hidrobromid |
| FR2932800B1 (fr) | 2008-06-20 | 2015-02-20 | Servier Lab | Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2933975B1 (fr) | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| FR2935381B1 (fr) | 2008-08-29 | 2010-12-17 | Servier Lab | Nouveau procede de resolution des enantiomerees du (3,4-dimethoxy-bicyclo°4.2.0!octa-1,3,5-trien-7-yl)nitrile et application a la synthese de l'ivabradine |
| CN101723897B (zh) * | 2008-10-31 | 2011-11-16 | 齐鲁制药有限公司 | 伊伐布雷定的合成方法 |
| EP2367782B1 (en) | 2008-12-22 | 2013-02-13 | KRKA, D.D., Novo Mesto | Process for preparation of ivabradine |
| FR2940287B1 (fr) * | 2008-12-24 | 2010-12-24 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| CN101768117B (zh) * | 2008-12-29 | 2014-05-07 | 北京德众万全药物技术开发有限公司 | 一种盐酸伊伐布雷定晶型及其制备方法 |
| CN101768116B (zh) * | 2008-12-29 | 2014-06-18 | 北京德众万全药物技术开发有限公司 | 一种伊伐布雷定的制备方法 |
| FR2941695B1 (fr) * | 2009-02-04 | 2011-02-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| ME00986B (me) | 2009-03-31 | 2012-06-20 | Servier Lab | Novi postupak sinteze ivabradina i njegovih adicionih soli sa farmaceutski prihvatljivom kiselinom |
| FR2943667B1 (fr) * | 2009-03-31 | 2011-05-06 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| WO2010128525A2 (en) | 2009-05-04 | 2010-11-11 | Dinesh Shantilal Patel | A formulation of ivabradine for treating the cardiovascular disease |
| SI23290A (sl) | 2010-02-12 | 2011-08-31 | Krka D.D., Novo Mesto | Nove oblike ivabradin hidroklorida |
| FR2956401B1 (fr) * | 2010-02-17 | 2012-02-03 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| WO2011104723A2 (en) * | 2010-02-23 | 2011-09-01 | Ind-Swift Laboratories Limited | Acid addition salts of ivabradine and preparation thereof |
| HUP1000245A2 (en) * | 2010-05-07 | 2011-11-28 | Richter Gedeon Nyrt | Industrial process for the production ivabradin salts |
| TWI499587B (zh) * | 2010-06-03 | 2015-09-11 | Jiangsu Hengrui Medicine Co | 硫酸伊伐佈雷定及其ｉ型結晶的製備方法 |
| PT2579858E (pt) | 2010-06-14 | 2014-07-18 | Ratiopharm Gmbh | Composição farmacêutica que contém ivabradina |
| WO2012025940A1 (en) | 2010-08-25 | 2012-03-01 | Cadila Healthcare Limited | Polymorphic form of ivabradine hydrochloride and process for preparation thereof |
| FR2971507B1 (fr) * | 2011-02-14 | 2013-01-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| CN102304088B (zh) * | 2011-07-07 | 2013-06-19 | 石药集团欧意药业有限公司 | 一种伊伐布雷定化合物、制备方法及其药物组合物 |
| EP2726462B1 (en) | 2011-08-02 | 2017-03-22 | Sandoz AG | Acetone solvate of ivabradine hydrochloride |
| EP2773621B1 (en) | 2011-11-04 | 2015-12-30 | Synthon BV | A process for making crystalline delta-form of ivabradine hydrochloride |
| EP2589594A1 (en) | 2011-11-04 | 2013-05-08 | Urquima S.A. | Ivabradine hydrochloride Form IV |
| WO2013102919A1 (en) | 2011-11-14 | 2013-07-11 | Cadila Healthcare Limited | Polymorphic forms of ivabradine hydrochloride |
| FR2984320B1 (fr) * | 2011-12-20 | 2013-11-29 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2984319B1 (fr) * | 2011-12-20 | 2013-12-27 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2986804A1 (fr) * | 2012-02-09 | 2013-08-16 | Servier Lab | Procede de synthese enzymatique de l'acide (7s) 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene 7-carboxylique ou de ses esters, et application a la synthese de l'ivabradine et de ses sels |
| FR2988720B1 (fr) * | 2012-03-27 | 2014-03-14 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2993561B1 (fr) * | 2012-07-17 | 2014-10-31 | Servier Lab | Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels |
| CN103848789B (zh) * | 2012-11-29 | 2016-05-18 | 江苏恒瑞医药股份有限公司 | 一种伊伐布雷定的制备方法 |
| CN103012268B (zh) * | 2013-01-05 | 2015-02-25 | 江苏宇田生物医药科技有限公司 | 一种伊伐布雷定制备方法 |
| EP2948432B1 (en) | 2013-01-24 | 2018-09-19 | Synthon BV | Process for making ivabradine |
| ITMI20130684A1 (it) * | 2013-04-24 | 2014-10-25 | Chemo Res S L | Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione |
| ITMI20130416A1 (it) * | 2013-03-19 | 2014-09-20 | Chemo Res S L | Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione |
| EP2781509B2 (en) | 2013-03-19 | 2023-06-14 | Chemo Research, S.L. | New polymorph of ivabradine hydrochloride and method for its preparation |
| CZ2013767A3 (cs) | 2013-10-02 | 2015-04-29 | Zentiva, K.S. | Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice |
| MX363389B (es) | 2013-12-12 | 2019-03-20 | Synthon Bv | Composicion farmaceutica que comprende ivabradina amorfa. |
| CN103864690B (zh) * | 2014-01-06 | 2016-09-14 | 北京莱瑞森医药科技有限公司 | 伊伐布雷定盐酸盐的s晶型、其制备方法和药物组合物 |
| ES2717715T3 (es) | 2014-02-14 | 2019-06-24 | Synthon Bv | Composición farmacéutica que comprende polimorfo IV de clorhidrato de ivabradina |
| CN103880748B (zh) * | 2014-04-03 | 2015-09-16 | 南京正大天晴制药有限公司 | 一种盐酸伊伐布雷定结构类似物及其制备方法和应用 |
| CZ2014478A3 (cs) | 2014-07-10 | 2015-09-16 | Zentiva, K.S. | Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice |
| WO2016102423A1 (en) | 2014-12-22 | 2016-06-30 | Ratiopharm Gmbh | Composition comprising ivabradine in a dissolved form |
| EP3101010A1 (en) | 2015-06-03 | 2016-12-07 | Urquima S.A. | New method for the preparation of highly pure ivabradine base and salts thereof |
| CN107056706B (zh) * | 2015-12-21 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种用于制备盐酸伊伐布雷定α晶型的方法 |
| TR201703066A2 (tr) | 2017-02-28 | 2018-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari |
| EP3366282B1 (en) | 2017-02-28 | 2025-10-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
| US20230140818A1 (en) | 2017-04-27 | 2023-05-04 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
| US20230181472A1 (en) | 2018-10-30 | 2023-06-15 | Amgen Inc. | Process of making ivabradine hydrochloride drug product |
| IT202000025312A1 (it) | 2020-10-26 | 2022-04-26 | Cambrex Profarmaco Milano S R L | Processi per la preparazione di polimorfi di ivabradina hcl |
| CN115286577B (zh) * | 2022-08-25 | 2023-10-20 | 江苏永安制药有限公司 | 一种盐酸伊伐布雷定及其中间体的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3119874A1 (de) | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| DE3418270A1 (de) | 1984-05-17 | 1985-11-21 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| EP0204349A3 (de) | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE3519735A1 (de) * | 1985-06-01 | 1986-12-04 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| FR2681862B1 (fr) | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
| FR2834896B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'ivabradine |
| FR2868776B1 (fr) * | 2004-04-13 | 2008-04-18 | Servier Lab | Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2868775B1 (fr) * | 2004-04-13 | 2008-04-11 | Servier Lab | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2882556B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2882554B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2882555B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2882553B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2891827B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2891826B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
-
2004
- 2004-04-13 FR FR0403830A patent/FR2868777B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-07 CA CA2496723A patent/CA2496723C/fr not_active Expired - Lifetime
- 2005-02-07 AP AP2005003222A patent/AP1821A/xx active
- 2005-02-14 CU CU20050034A patent/CU23465B7/es unknown
- 2005-02-14 US US11/057,492 patent/US7176197B2/en not_active Expired - Lifetime
- 2005-02-15 CR CR7691A patent/CR7691A/es unknown
- 2005-02-15 CO CO05013707A patent/CO5670092A1/es not_active Application Discontinuation
- 2005-02-15 SG SG200500771A patent/SG116575A1/en unknown
- 2005-02-17 EC EC2005005610A patent/ECSP055610A/es unknown
- 2005-02-18 MY MYPI20050620A patent/MY141194A/en unknown
- 2005-02-18 NO NO20050884A patent/NO329807B1/no unknown
- 2005-02-18 AR ARP050100588A patent/AR047745A1/es active IP Right Grant
- 2005-02-18 OA OA1200500056A patent/OA12913A/en unknown
- 2005-02-18 CN CNB2005100517790A patent/CN1305856C/zh not_active Expired - Lifetime
- 2005-02-18 UA UAA200501522A patent/UA80834C2/xx unknown
- 2005-02-18 MA MA28114A patent/MA27600A1/fr unknown
- 2005-02-18 UY UY28759A patent/UY28759A1/es not_active Application Discontinuation
- 2005-02-18 GE GEAP8649A patent/GEP20074138B/en unknown
- 2005-02-18 JP JP2005041812A patent/JP4515934B2/ja not_active Expired - Lifetime
- 2005-02-18 NI NI200500031A patent/NI200500031A/es unknown
- 2005-02-18 NZ NZ538326A patent/NZ538326A/en not_active IP Right Cessation
- 2005-02-18 AU AU2005200861A patent/AU2005200861B2/en not_active Expired
- 2005-02-18 ZA ZA2005/01466A patent/ZA200501466B/en unknown
- 2005-02-19 KR KR1020050013859A patent/KR100677019B1/ko not_active Expired - Lifetime
- 2005-02-19 SA SA05260016A patent/SA05260016B1/ar unknown
- 2005-02-21 ES ES05290381T patent/ES2285651T3/es not_active Expired - Lifetime
- 2005-02-21 PT PT05290381T patent/PT1589005E/pt unknown
- 2005-02-21 DE DE602005000765T patent/DE602005000765T2/de not_active Expired - Lifetime
- 2005-02-21 SI SI200530017T patent/SI1589005T1/sl unknown
- 2005-02-21 BR BRPI0500585A patent/BRPI0500585B8/pt not_active IP Right Cessation
- 2005-02-21 DK DK05290381T patent/DK1589005T3/da active
- 2005-02-21 ME MEP-2007-219A patent/ME01396B/me unknown
- 2005-02-21 PL PL05290381T patent/PL1589005T3/pl unknown
- 2005-02-21 EP EP05290381A patent/EP1589005B1/fr not_active Expired - Lifetime
- 2005-02-21 AT AT05290381T patent/ATE358123T1/de active
- 2005-02-21 IL IL167013A patent/IL167013A/en active IP Right Grant
- 2005-02-21 EA EA200500238A patent/EA007745B1/ru unknown
- 2005-02-21 RS RSP-2007/0219A patent/RS50511B/sr unknown
- 2005-02-21 WO PCT/FR2005/000394 patent/WO2005110993A1/fr not_active Ceased
- 2005-04-07 MX MXPA05003694A patent/MXPA05003694A/es active IP Right Grant
-
2006
- 2006-01-05 HK HK06100189.5A patent/HK1080362B/zh not_active IP Right Cessation
-
2007
- 2007-01-18 US US11/654,719 patent/US7867994B2/en active Active
- 2007-05-16 CY CY20071100664T patent/CY1106597T1/el unknown
- 2007-05-29 HR HR20070246T patent/HRP20070246T5/xx unknown
-
2009
- 2009-09-25 JP JP2009220557A patent/JP4848449B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-05 CR CR11780A patent/CR11780A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01396B (me) | Postupak za sintezu ivabradina i njegovih farmaceutski prihvatljivih aditivnih soli kiselina | |
| AU2006228027B2 (en) | Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
| CN101472880A (zh) | 生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法 | |
| JP5277130B2 (ja) | １，３，４，５−テトラヒドロ−２ｈ−３−ベンゾアゼピン−２−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 | |
| HK56897A (en) | Benzocyclobutyl- or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases | |
| RS50512B (sr) | Postupak za izradu (1s)-4,5-dimetoksi-1-(metilaminometil)- benzociklobutana i njegovih aditivnih soli kiselina kao i njegova primena za sintezu ivabradina i njegovih farmaceutski prihvatljivih aditivnih soli kiselina | |
| AU2006228028A1 (en) | delta-d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
| CA2537400A1 (fr) | Forme cristalline .gamma. du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| JP2010150259A (ja) | イバブラジン及び薬学的に許容されうる酸とのその付加塩の合成のための新たな方法 | |
| JP5670406B2 (ja) | イバブラジン及び薬学的に許容しうる酸とのその付加塩の新規合成方法 | |
| JP5531084B2 (ja) | イバブラジン及びその薬学的に許容され得る酸との付加塩の新規な合成方法 | |
| TW200817334A (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| HK1079777B (en) | Process for the synthesis of 1,3,4,5-tetrahydro-2h-3-benzazepin-2-one compounds, and application thereof |